RT Journal Article
SR Electronic
T1 Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 480
OP 483
DO 10.1136/ijgc-2020-001747
VO 31
IS 3
A1 Dimitrios Nasioudis
A1 Lakeisha Mulugeta-Gordon
A1 Erin McMinn
A1 Maureen Byrne
A1 Emily M Ko
A1 Lori Cory
A1 Ashley F Haggerty
A1 Nawar A Latif
YR 2021
UL http://ijgc.bmj.com/content/31/3/480.abstract
AB Objective Fertility-sparing surgery is rarely offered for patients with stage II epithelial ovarian carcinoma. The aim of the present study was to evaluate the overall survival of pre-menopausal patients with stage II epithelial ovarian carcinoma who did not undergo hysterectomy.Methods The National Cancer Database was accessed, and patients aged ≤40 years without a history of another tumor diagnosed between 2004 and 2015 with a pathological stage II epithelial ovarian carcinoma, who underwent lymphadenectomy and received multi-agent chemotherapy, were identified. Overall survival was compared with the log-rank test after generation of Kaplan–Meier curves. A Cox model was constructed to control for tumor histology.Results A total of 185 patients met the inclusion criteria. The rate of uterine preservation was 24.3% (45 patients). Patients who did not undergo hysterectomy were younger (median 32 vs 37 years, p<0.001) and less likely to have high-grade tumors compared with those who underwent hysterectomy. The two groups were comparable in terms of presence of co-morbidities and performance of adequate lymphadenectomy (p>0.05). Median follow-up of the present cohort was 62.3 months (95% CI 53.6 to 71.0) and a total of 22 deaths occurred. There was no difference in overall survival between patients who did and did not undergo hysterectomy (p=0.50; 5-year overall survival rates 87.5% and 91.4%, respectively). After controlling for tumor histology, grade and substage, omission of hysterectomy was not associated with worse survival (HR 0.69, 95% CI 0.22 to 2.12).Conclusions Uterine preservation was not associated with worse survival in this cohort of pre-menopausal patients with stage II epithelial ovarian carcinoma.Data may be obtained from a third party and are not publicly available. Data are available from the American College of Surgeons.